A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

761

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle-invasive Bladder Cancer

Interventions

DRUG: Atezolizumab
OTHER: Placebo
DEVICE: Signatera

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]